Operating Income (Loss) in USD of Eiger BioPharmaceuticals, Inc. from 2012 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Eiger BioPharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and change rate from 2012 to Q4 2023.
  • Eiger BioPharmaceuticals, Inc. Operating Income (Loss) for the quarter ending 31 Dec 2023 was -$12.6M, a 48.5% increase year-over-year.
  • Eiger BioPharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending 31 Dec 2023 was -$71.8M, a 22.6% increase year-over-year.
  • Eiger BioPharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$71.8M, a 22.6% increase from 2022.
  • Eiger BioPharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$92.7M, a 20.5% decline from 2021.
  • Eiger BioPharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$76.9M, a 23.8% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Eiger BioPharmaceuticals, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2023 -$71.8M -$12.6M +$11.9M +48.5% 01 Oct 2023 31 Dec 2023 10-K 08 Apr 2024
Q3 2023 -$83.6M -$16.9M +$9.44M +35.8% 01 Jul 2023 30 Sep 2023 10-Q 09 Nov 2023
Q2 2023 -$93.1M -$20M +$99K +0.49% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2023
Q1 2023 -$93.2M -$22.3M -$443K -2.03% 01 Jan 2023 31 Mar 2023 10-Q 11 May 2023
Q4 2022 -$92.7M -$24.5M -$3.56M -17% 01 Oct 2022 31 Dec 2022 10-K 08 Apr 2024
Q3 2022 -$89.2M -$26.4M -$4.52M -20.7% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 -$84.7M -$20.1M -$1.72M -9.36% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 -$82.9M -$21.8M -$6.01M -38% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023
Q4 2021 -$76.9M -$20.9M -$2.95M -16.4% 01 Oct 2021 31 Dec 2021 10-K 17 Mar 2023
Q3 2021 -$74M -$21.9M -$7.01M -47.3% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022
Q2 2021 -$67M -$18.4M -$3.73M -25.5% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022
Q1 2021 -$63.2M -$15.8M -$1.09M -7.41% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022
Q4 2020 -$62.1M -$18M -$1.45M -8.79% 01 Oct 2020 31 Dec 2020 10-K 17 Mar 2023
Q3 2020 -$60.7M -$14.8M +$3.47M +19% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021
Q2 2020 -$64.2M -$14.6M +$2.53M +14.8% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021
Q1 2020 -$66.7M -$14.7M +$2.2M +13% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021
Q4 2019 -$68.9M -$16.5M -$419K -2.6% 01 Oct 2019 31 Dec 2019 10-K 10 Mar 2022
Q3 2019 -$68.5M -$18.3M -$1.47M -8.71% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020
Q2 2019 -$67M -$17.2M -$7.55M -78.6% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020
Q1 2019 -$59.5M -$16.9M -$8.42M -99% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020
Q4 2018 -$51M -$16.1M -$5.51M -52% 01 Oct 2018 31 Dec 2018 10-K 09 Mar 2021
Q3 2018 -$45.5M -$16.8M -$7.97M -89.8% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019
Q2 2018 -$37.6M -$9.61M +$1.47M +13.3% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019
Q1 2018 -$39M -$8.51M +$2.48M +22.6% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019
Q4 2017 -$41.5M -$10.6M +$2.32M +18% 01 Oct 2017 31 Dec 2017 10-K 13 Mar 2020
Q3 2017 -$43.8M -$8.87M +$2.46M +21.7% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018
Q2 2017 -$46.3M -$11.1M +$2.12M +16.1% 01 Apr 2017 30 Jun 2017 10-Q 10 Aug 2018
Q1 2017 -$48.4M -$11M -$2.31M -26.6% 01 Jan 2017 31 Mar 2017 10-Q 11 May 2018
Q4 2016 -$46.1M -$12.9M -$6.2M -92.4% 01 Oct 2016 31 Dec 2016 10-K 14 Mar 2019
Q3 2016 -$39.9M -$11.3M -$8.46M -295% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017
Q2 2016 -$31.5M -$13.2M -$10.6M -411% 01 Apr 2016 30 Jun 2016 10-Q 11 Aug 2017
Q1 2016 -$20.8M -$8.68M -$7.87M -979% 01 Jan 2016 31 Mar 2016 10-Q 12 May 2017
Q4 2015 -$13M -$6.71M -$27.3M -133% 01 Oct 2015 31 Dec 2015 10-K 09 Mar 2018
Q3 2015 $14.3M -$2.87M +$5.26M +64.7% 01 Jul 2015 30 Sep 2015 10-Q 08 Nov 2016
Q2 2015 $9.02M -$2.59M +$4.42M +63.1% 01 Apr 2015 30 Jun 2015 10-Q 10 Aug 2016
Q1 2015 $4.6M -$804K +$6.12M +88.4% 01 Jan 2015 31 Mar 2015 10-Q 16 May 2016
Q4 2014 -$1.52M $20.5M +$7.51M +57.6% 01 Oct 2014 31 Dec 2014 10-K 23 Mar 2017
Q3 2014 -$9.03M -$8.13M -$2.61M -47.2% 01 Jul 2014 30 Sep 2014 10-Q 09 Nov 2015
Q2 2014 -$6.42M -$7.01M -$2.01M -40.3% 01 Apr 2014 30 Jun 2014 10-Q 11 Aug 2015
Q1 2014 -$4.4M -$6.92M -$3.45M -99.4% 01 Jan 2014 31 Mar 2014 10-Q 15 May 2015
Q4 2013 -$953K $13M 01 Oct 2013 31 Dec 2013 8-K/A 17 Jun 2016
Q3 2013 -$5.52M 01 Jul 2013 30 Sep 2013 10-Q 12 Nov 2014
Q2 2013 -$4.99M 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014
Q1 2013 -$3.47M 01 Jan 2013 31 Mar 2013 10-Q 13 May 2014

Eiger BioPharmaceuticals, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$71.8M +$21M +22.6% 01 Jan 2023 31 Dec 2023 10-K 08 Apr 2024
2022 -$92.7M -$15.8M -20.5% 01 Jan 2022 31 Dec 2022 10-K 08 Apr 2024
2021 -$76.9M -$14.8M -23.8% 01 Jan 2021 31 Dec 2021 10-K 17 Mar 2023
2020 -$62.1M +$6.76M +9.8% 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2023
2019 -$68.9M -$17.9M -35% 01 Jan 2019 31 Dec 2019 10-K 10 Mar 2022
2018 -$51M -$9.53M -22.9% 01 Jan 2018 31 Dec 2018 10-K 09 Mar 2021
2017 -$41.5M +$4.6M +9.97% 01 Jan 2017 31 Dec 2017 10-K 13 Mar 2020
2016 -$46.1M -$33.1M -256% 01 Jan 2016 31 Dec 2016 10-K 14 Mar 2019
2015 -$13M -$11.5M -756% 01 Jan 2015 31 Dec 2015 10-K 09 Mar 2018
2014 -$1.52M -$563K -59.1% 01 Jan 2014 31 Dec 2014 10-K 23 Mar 2017
2013 -$953K +$15M +94% 01 Jan 2013 31 Dec 2013 8-K/A 17 Jun 2016
2012 -$15.9M 01 Jan 2012 31 Dec 2012 10-K 31 Mar 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.